Clinical trials: Follow-Up Study
Multiple Sclerosis, Relapsing-Remitting
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and…
- Trial name
- Beyond (NCT00459667)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 184 sites in United States, Argentina and 24 more
- Volunteers
- 1,420 people
- Sponsor
- Bayer
Cataract Senile
Evaluation of Glistening, Visual Outcomes and General Safety 24 Months Post-IOL Implantation
Main evaluation of glistening at least 24 Months post-IOL implantation
- Trial name
- NCT07297719
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Carl Zeiss Meditec AG
Osteoporotic Fractures, Osteoporosis, Postmenopausal
A 5-Year Follow-up Study Investigating Factors Associated With Osteoporotic Fracture in Chinese Postmenopausal Women
This proposed study was designed to investigate the prevalence of a 5-year incident osteoporotic fracture and evaluate the association of a 5-year change of 25-hydroxyvitamin D (25[OH]D)/bone turnover makers/bone mineral density…
- Trial name
- PK-VF (NCT02247011)
- Testing
- Questionaire survey, Bone mineral density examination, Vertebral fracture assessment
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Growth and Development
Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus
The primary objective of CRAD001M2305 was to report the long-term effects of everolimus treatment on height, weight and sexual development (using Tanner Stages) in children and adolescents with Tuberous Sclerosis Complex…
- Trial name
- EXIST-LT (NCT02338609)
- Testing
- Everolimus
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Syndrome
Tolerability, Safety and Efficacy of Lubricin Versus Sodium Hyaluronate Eye Drops in Patients With Moderate Dry Eye
The objective of this study is to evaluate tolerability, safety and efficacy of Lubricin 150 µg/ml eye drops when compared to a widely used commercial 0.18% sodium hyaluronate eye drop formulation in moderate dry eye patients.
- Trial name
- NCT02507934
- Testing
- Lubricin, Sodium Hyaluronate
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Dompé Farmaceutici S.p.A
Lung Cancer
Telephonic Contact and Subsequent Physical Follow up Treated Lung Cancer Patients
Does the routine clinical practice of follow up after primary treatment in lung cancer patients has any utility.
- Trial name
- TELE001 (NCT01133067)
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Tata Memorial Hospital
Cystinosis
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
Cystinosis is an inherited disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate immediate release) which must be taken every…
- Trial name
- NCT01197378
- Testing
- Cysteamine Bitartrate Delayed-release Capsules
- Where
- 10 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
To continue to assess the clinical safety and efficacy of Certolizumab Pegol as add-on therapy with stable-dose Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Trial name
- CERTAIN 2 (NCT00843778)
- Testing
- Certolizumab Pegol
- Where
- 25 sites in Austria, France and 3 more
- Volunteers
- 131 people
- Sponsor
- UCB Pharma
Diabetes Mellitus, Type 2
New Patient Support Program in Type 2 Diabetes
Non-profit observational study on the role of the community pharmacist and the "pharmacy of services" in the case management of the diabetic patient
- Trial name
- NCT03752567
- Testing
- Follow up
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Farmacia La Regina s.r.l.
Open Surgery, Blood Vessels, Lymphatic Ducts and Nerves
PRIMO Post-Market Clinical Follow Up Study
Post Market Clinical Follow up Study aimed to collect clinical data on safety and efficacy of Robotically Assisted System called Symani to perform microsurgery techniques such as anastomosis, suturing and ligation for open…
- Conditions
- Open Surgery, Blood Vessels, Lymphatic Ducts and Nerves, Free Flaps
- Trial name
- PRIMO (NCT04843436)
- Testing
- Symani Surgical System
- Where
- 10 sites in Austria, Belgium and 5 more
- Volunteers
- 427 people
- Sponsor
- MMI (Medical Microinstruments, Inc.)
Multiple Sclerosis, Clinically Isolated Syndrome
Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)
REFLEXION is a double blind extension of the study 27025 (NCT00404352) (REFLEX). The purpose of the study is to obtain long-term follow-up data in subjects with clinically definite multiple sclerosis (MS) and subjects with a…
- Trial name
- REFLEXION (NCT00813709)
- Testing
- RNF
- Where
- 57 sites in Argentina, Austria and 22 more
- Volunteers
- 402 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Multiple Sclerosis
Atacicept in Multiple Sclerosis Extension Study, Phase II
This study (28851) is a long-term follow-up study of subjects enrolled in ATAMS study 28063 (NCT00642902). The aim of this study is to monitor the safety and tolerability of atacicept administered for up to 5 years to subjects…
- Trial name
- ATAMS ext (NCT00853762)
- Testing
- Atacicept 25 mg, Atacicept 75 mg, Atacicept 150 mg
- Where
- 47 sites in United States, Australia and 15 more
- Volunteers
- 74 people
- Sponsor
- EMD Serono
Bankart Lesions, SLAP Lesion
PMCF Study on the Safety, Performance and Clinical Benefits Data of the ToggleLoc™ 2.9mm and JuggerLoc™ in the Shoulder
The study is a multicenter, retrospective, non-randomized, non-controlled and consecutive series post-market study. The purpose of this study is to collect data confirming safety, performance and clinical benefits of the…
- Conditions
- Bankart Lesions, SLAP Lesion, Acromioclavicular; Dislocation, Capsular Shift/Capsulolabral Reconstruction
- Trial name
- NCT05584553
- Testing
- ToggleLoc 2.9 mm soft tissue device, JuggerLoc soft tissue device
- Where
- 3 sites in United States, Spain
- Volunteers
- 214 people
- Sponsor
- Zimmer Biomet
Diabetes
Routine Use of Sensor-Augmented Pump Therapy - a Follow up Study
The aim of this study is to document the routine practice in continuous glucose monitoring (CGM) in patients treated with sensor-augmented pump therapy and to assess clinical outcome (HbA1c) before the start of the sensor use to…
- Trial name
- NCT01451372
- Where
- Sweden
- Volunteers
- 69 people
- Sponsor
- Medtronic MiniMed, Inc.
Chronic Venous Insufficiency
EU Post Market Clinical Follow-Up Study of the Venclose System for Saphenous Vein Incompetence
This is a prospective, non-randomized study in which patients who meet eligibility criteria and consent to participate will undergo a minimally invasive procedure using radiofrequency (RF) energy for ablation of the great…
- Trial name
- NCT04236245
- Testing
- Venclose RF System
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Venclose, Inc.
Rosacea
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.
- Trial name
- NCT02576860
- Testing
- CLS001 (Omiganan), Vehicle
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Edentulism
Study to Evaluate an Implant With a Sloped Top in Patients With a Sloped Jaw Bone
The study aims to evaluate maintenance of lingual/palatinal marginal bone with the (ASTRA TECH Implant System) OsseoSpeed™ Profile implant in sites where the alveolar crest anatomy is sloped in a lingual to buccal direction.
- Trial name
- NCT00807456
- Testing
- ASTRA TECH Implant System, OsseoSpeed™
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- Dentsply Sirona Implants and Consumables
Japanese Encephalitis
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
The study investigates long-term immunity and safety of IC51 (IXIARO®, JESPECT®) in a pediatric population vaccinated in the parent study IC51-322.
- Trial name
- NCT01246479
- Testing
- Blood draw, IC51 has given in the parent study IC51-322
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Signs of Facial Aging With Volume Loss in the Upper Cheeks, Nasolabial Folds and Marionette Lines
Safety, Effectiveness and Participant Satisfaction Study of a Dermal Filler (of RADIESSE® (+) Lidocaine) in the Treatment of Ageing Signs in the Face
The primary objective is to collect clinical data to confirm performance and safety for RADIESSE® (+) Lidocaine, when used in accordance with its labelling in the treatment of nasolabial folds, marionette lines and/or upper cheek…
- Trial name
- RaLido (NCT03650387)
- Testing
- RADIESSE® (+) Lidocaine
- Where
- 7 sites in Germany
- Volunteers
- 207 people
- Sponsor
- Merz North America, Inc.
Attention Deficit Disorder With Hyperactivity
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Trial 42603ATT3004 is an open-label extension study to clinical trial 42603ATT3002 (NCT00246220). In trial 42603ATT3002 the efficacy and safety of OROS methylphenidate was assessed in adult subjects with Attention Deficit…
- Trial name
- NCT00307684
- Testing
- double blind PR OROS methylphenidate, open label PR OROS methylphenidate
- Where
- 21 sites in France, Germany and 5 more
- Volunteers
- 155 people
- Sponsor
- Janssen-Cilag International NV